![Dan Dan Dong](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dan Dan Dong
Directeur/Membre du Conseil chez
INNOCARE PHARMA LIMITED
Profil
Dan Dan Dong is the founder of Shanghai Rarestone Health Tech Group Co., Ltd. Dr. Dong is an Independent Non-Executive Director at InnoCare Pharma Ltd. since 2023.
Dr. Dong is an Executive Director at VISEN Pharmaceuticals (Shanghai) Co., Ltd. since 2021.
Formerly, Dr. Dong was a Director at VISEN Pharmaceuticals from 2019 to 2023.
Dr. Dong was Chief Business Officer at Arrivent BioPharma, Inc. Dr. Dong completed an undergraduate degree at Sichuan University in 2006.
Dr. Dong earned a doctorate from Fudan University in 2011.
Postes actifs de Dan Dan Dong
| Sociétés | Poste | Début |
|---|---|---|
| INNOCARE PHARMA LIMITED | Directeur/Membre du Conseil | 11/10/2023 |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Directeur/Membre du Conseil | 07/11/2018 |
Anciens postes connus de Dan Dan Dong
| Sociétés | Poste | Fin |
|---|---|---|
| VISEN PHARMACEUTICALS | Directeur/Membre du Conseil | 13/12/2023 |
Vivo Capital LLC
 Vivo Capital LLC Investment ManagersFinance Vivo Capital invests in both public and private middle market companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceutical, healthcare and life science sectors. It provides financing for early stage, growth stage, buyouts, spin-offs and restructurings. The firm also acquires controlling interest. It acts as lead investor and also makes co-investments. | Corporate Officer/Principal | 01/07/2021 |
Shanghai Rarestone Health Tech Group Co. Ltd.
 Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and supplies rare disease pharmaceutical products & provides medical services | Fondateur | - |
| ARRIVENT BIOPHARMA, INC. | Corporate Officer/Principal | - |
Formation de Dan Dan Dong
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
92
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital invests in both public and private middle market companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceutical, healthcare and life science sectors. It provides financing for early stage, growth stage, buyouts, spin-offs and restructurings. The firm also acquires controlling interest. It acts as lead investor and also makes co-investments. | Finance |
Sichuan University
 Sichuan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fudan University
 Fudan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
InnoCare Pharma Ltd.
 InnoCare Pharma Ltd. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs for the treatment of cancer and autoimmune diseases | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. BiotechnologyHealth Technology Develops endocrine disease therapies | Health Technology |
Arrivent BioPharma, Inc.
 Arrivent BioPharma, Inc. Pharmaceuticals: OtherHealth Technology Engages in development and commercialization of cancer medicines | Health Technology |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and supplies rare disease pharmaceutical products & provides medical services | Health Technology |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
